XYDALBA™ (dalbavancin hydrochloride) is a second generation, semi-synthetic lipoglycopeptide, which consists of a lipophilic side-chain added to an enhanced glycopeptide backbone. XYDALBA demonstrates bactericidal activity in vitro against a range of Gram-positive bacteria, such as Staphylococcus aureus (including methicillin-resistant, also known as MRSA, strains) and Streptococcus pyogenes, as well as certain other streptococcal species.
Where licensed, Correvio may commercialise XYDALBA under agreement with Allergan plc in France, the UK, Germany, Belgium, Nordic nations, certain other Western European nations, various Middle Eastern nations, and Canada.
The current XYDALBA Summary of Product Characteristics, in all EU languages, can be found here